Grace Therapeutics, Inc. Income Statement
GRCE|1 years of annual SEC 10-K data (FY2023-FY2023)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
Grace Therapeutics, Inc. reported $100M in revenue and $10M in net loss for FY2023. Its profit margin was -9.8% in FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.68 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 |
|---|---|
| Revenue | $100.0M |
| SG&A Expense | $9.3M |
| R&D Expense | $5.6M |
| Operating Income | -$15.6M |
| Income Tax | -$648.0K |
| Net Income | -$9.8M |
| EPS (Basic) | -$0.27 |
| EPS (Diluted) | -$0.27 |
| Shares Outstanding | 44.3M |
| Operating Margin | -15.6% |
| Profit Margin | -9.8% |